Anti-thrombotic drug candidate

Dr. Neil Hayward, co-founder, President, and CEO at eXIthera Pharmaceuticals, Inc., discusses the need for a new anti-thrombotic drug and how eXIthera is addressing that need with their lead product candidate EP-7041.  The next step for EP-7041 is Phase 2 clinical trials on cardiac surgery patients.

Addressing the Need for an Effective Anticoagulant

Technology Networks recently spoke with Dr Neil Hayward Ph.D., CEO at eXIthera Pharmaceuticals to learn more about the role of the intrinsic and extrinsic pathways, and how they are exploiting coagulation mechanisms to develop antithrombotic therapeutics.

JPMorgan 2020 – ForbesBOOKS interview with Dr. Neil Hayward

Neil Hayward, Ph.D. is CEO of eXIthera; eXIthera is the leader in Factor XIa inhibition, the ideal target for anticoagulation. Their drug candidates are small molecules that prevent thrombosis without an increased risk in bleeding.

2020: Year in Preview — What if Funding Novel Ideas Was More Equitable?

Many innovative medicines are in the pipeline. But new funding approaches will be needed to make sure there is a greater chance that they are brought to market. Dr. Neil Hayward is included as one of PharmaVOICE‘s 130 industry experts and was posed 20 provocative questions, focusing on how influencers think about aspirational goals in terms […]

2020: Year in Preview — Technology Plus Science: New Company Model?

For more than a decade we have been discussing the role that technology and nontraditional partners would play to move the industry toward a more efficient business model — one based more on health outcomes than product sales. Dr. Neil Hayward is included as one of PharmaVOICE‘s 130 industry experts and was posed 20 provocative questions, […]

2020: Year in Preview — Wearing Your health: The Case for Smart Clothing

As the wearable market continues to expand, the potential for smart clothing to monitor and manage health is breaking new ground. Dr. Neil Hayward is included as one of PharmaVOICE‘s 130 industry experts and was posed 20 provocative questions, focusing on how influencers think about aspirational goals in terms of health, what needs to happen to […]

Companies To Watch: eXIthera

The name of this company, eXIthera, refers to its therapeutic aim, inhibiting Factor XIa, a new target that may offer a way to avoid the bleeding problems with current anticoagulants. Its lead drug, an injectable coded EP-7041, has completed a Phase 1 clinical trial in healthy human subjects and moved to a program in cardiac […]

Overcoming The Hurdles of Starting up a Biopharmaceutical Company

Every emerging biopharmaceutical company has an interesting story that describes how they overcame major startup challenges, including study design, funding, and drug targeting strategies. eXIthera is developing a small molecule, EP-7041, to control the blood-clotting pathway and enable healthy blood flow without the concerns of adverse clotting or major bleeding via selective inhibition of Factor […]

eXIthera CEO, Dr. Neil Hayward, is featured on the Cutting Edge Cast

eXIthera is doing big things with small molecules. This clinical-stage biotech company is developing therapies to maintain the balance between healthy blood flow and clotting, specifically during heart surgery. In today’s Cutting Edge Cast, eXIthera CEO Neil Hayward, Ph.D., explains why this therapy is critical for patients.

Cream of the clotbusters? eXIthera ‘teas’ off at AHA with strong Phase I data

eXIthera Pharmaceuticals Inc. CEO Neil Hayward told BioWorld he's hoping to build a "continuum of care" around factor XIa inhibitor EP-7041, after Phase I data showed the intravenous (I.V.) version of the antithrombotic safe and well-tolerated in healthy volunteers after single or multiple ascending intravenous doses – and even turned up some clues to efficacy.